- Altos Labs – a $3 billion biotech startup backed by Jeff Bezos – is on a mission to restore cell health and reverse diseases by rejuvenating cells labiotech.eu. It launched in 2022 with a dream of extending healthy human lifespan.
- Not about “cheating death”: Altos’s president Hans Bishop insists the focus is on extending “healthspan” (years of healthy life), with any longevity gains merely an “accidental consequence” fightaging.org. The company emphasizes improving life quality over pursuing immortality.
- Unprecedented talent & funding: Altos assembled a “dream team” of scientists – including Nobel laureate Shinya Yamanaka – by offering academic freedom and industry-level resources. Led by former GSK executive Hal Barron as CEO, and co-founded by biotech veterans Richard Klausner and Hans Bishop, Altos attracted $3 billion from prominent investors (Bezos, Yuri Milner, Arch Ventures) labiotech.eu en.wikipedia.org, making it one of the best-funded startups in biotech history.
- Racing a booming longevity industry: Altos Labs is part of a broader anti-aging biotech boom. Alphabet’s Calico Labs (launched 2013) was a pioneer, and newer startups like Retro Biosciences and Loyal have joined the fray – all aiming to extend healthy lifespan via cutting-edge science and drawing investments from Silicon Valley billionaires businessinsider.com 1 .
- Innovations in “rejuvenation” science: Altos and its peers are leveraging breakthroughs like partial cellular reprogramming – using Yamanaka factors to reset adult cells to a youthful state – which has shown promise in animals labiotech.eu labiotech.eu. Other approaches include senolytic drugs to clear aged “zombie” cells and gene therapies, all targeting aging at its biological roots.
- Early results signal hope: In 2024, Altos scientists published a landmark study demonstrating that partial reprogramming extended the lifespan of mice and improved health markers labiotech.eu. This evidence that aging may be reversible has been hailed as a major step toward translating rejuvenation technologies to humans.
- Competition and collaboration: Companies like Retro Biosciences (funded by OpenAI’s Sam Altman) aim to add 10+ years to human life through cell reprogramming and autophagy, planning their first clinical trials and reportedly seeking $1 billion for next steps labiotech.eu labiotech.eu. Loyal, which has raised over $125 million, is developing drugs to extend dogs’ lifespans as a springboard to human applications – and expects to launch the first FDA-approved longevity drug for pets by 2025 2 3
Inside Altos Labs: Jeff Bezos’s $3 Billion Bet to Reverse Aging
Stock Market Today
No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive
The IRS has not announced new federal stimulus payments for February 2026, and Congress has not approved fresh checks. Trump told NBC he is considering $2,000 tariff rebate checks but has not committed, saying any payout would likely come later in 2026. The IRS warns taxpayers to ignore texts and emails about “stimulus payments” and verify notices through official channels.
Tesla stock price rises to $411 as Musk solar hiring push and China AI plan set up week ahead
Tesla shares closed up 3.5% at $411.11 on Friday after news of a U.S. solar hiring push and an AI training center in China. The company targets 100 GW of U.S. solar manufacturing by 2028, far above current national output. Investors remain focused on Tesla’s autonomy and energy projects. Upcoming U.S. jobs and inflation data may affect market sentiment next week.
Palantir stock price rebounds to $135.90 on Cognizant AI deal — what to watch next week
Palantir shares closed Friday at $135.90, up 4.5% after Cognizant’s TriZetto unit announced plans to deploy Palantir Foundry and AIP in healthcare and business-process operations. The Dow closed above 50,000 for the first time. U.S. jobs and inflation data due next week may shift rate expectations for high-growth software stocks.
SoFi stock pops on back-to-back insider buys as jobs, CPI loom next week
SoFi shares jumped 7.2% to $20.86 Friday after heavy trading and insider stock purchases by two executives, SEC filings show. The moves come ahead of key U.S. jobs and inflation data next week, which could impact rate-sensitive lenders.
